Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab
author
Steg, P. Gabriel
Bhatt, Deepak L.
Danchin, Nicolas
Harrington, Robert A.
Jukema, J. Wouter
Liberopoulos, Evangelos
Marx, Nikolaus
statement of authorship
Emil Hagström, P. Gabriel Steg, Michael Szarek, Deepak L. Bhatt, Vera A. Bittner, Nicolas Danchin, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Evangelos Liberopoulos, Nikolaus Marx, [...], Margus Viigimaa
source
Circulation
publisher
journal volume number month
vol. 146, 9
year of publication
pages
p. 657 - 672
subject term
keyword
apolipoproteins B
cholesterol, LDL
heart disease risk factors
PCSK9 inhibitors
ISSN
0009-7322
notes
Bibliogr.: 41 ref
Open Access
Open Access
scientific publication
teaduspublikatsioon
classifier
category (general)
kvartiil
TTÜ department
language
inglise
Hagström, E., Steg, P.G., Szarek, M., Bhatt, D.L., Bittner, V.A., Danchin, N., Diaz, R., Goodman, S.G., Harrington, R.A., Jukema, J.W., Liberopoulos, E., Marx, N., Viigimaa, M. et al. Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab // Circulation (2022) vol. 146, 9, p. 657 - 672.